Safety and effectiveness of chronic hepatitis C virus infection treatment with fixed combination of sofosbuvir ande velpatasvir (Epclusa(R))
2016
Abstract
This is a review of basic pharmacological properties, therapeutical effects, and indications of a new preparation Epclusa. It contains both polymerase cofactor inhibitor (NS5A region of viral genome) velpatasvir and RNA-dependent RNA polymerase inhibitor sofosbuvir in a fixed-combination single tablet.
This preparation is the first to be effective against all basic genotypes of hepatitis C virus, thus having a very wide spectrum of indications. Advantages of this preparation include its high safety, almost 100% effectiveness, and especially the ease of use for the patients.